Founding offer · lifetime membership for a single £24, exclusive to our first members · closes 20 June Claim your place →
Global Research Partnerships £24 Lifetime Log inCreate free account

Funded Projects › HORIZON

SynEry · Bottom-up reconstruction of a Synthetic Erythrocyte

HORIZONStatus: SIGNED1 April 202230 September 2026EU funding €3,685,550Call HORIZON-EIC-2021-PATHFINDEROPEN-01

Blood is a precious and vital resource for many clinical interventions. Erythrocytes, its key component, are used to save thousands of lives every day worldwide. Yet, in low- and middle-income countries, its scarcity and unsafe control are endemic burdens that cost lives. In spite of several decades of attempts to develop a safe and universal blood substitute, this goal has yet to be achieved. Beyond the mere transport of gasses, erythrocytes have evolved together with their host organisms to perform very specialized functions. It is now clear that much of their complexity is indispensable to establish effective cardiovascular regulation. Yet, reproducing this complexity in a synthetic, functional facsimile is a challenging endeavour that requires new methods and multidisciplinary approaches. The ambitious goal of SynEry is to reproduce, in an advanced lipid vesicle, the following key features of erythrocytes: adequate lipid asymmetry with raft-like nanodomains; integration of essential functional proteins (both cytosolic and transmembrane) and a biomimetic cytoskeleton (conferring durability, flexibility and biconcavity); enhanced immune tolerability; responsivity to environmental cues (such as under deformation and hypoxia). These goals will be tackled by an interdisciplinary consortium bringing expertise on: droplet-based microfluidics combined with interfacial self-assembly of biofunctionalized nanoparticles (to build complex biomimetic membranes with ordered cytoskeletal nanodomains); DNA origami and self-assembling peptide technologies (to reconstruct a biomimetic cell cortex); and in-vivo testing models (to verify biocompatibility and functionality). The knowledge gained by producing a synthetic erythrocyte, is envisioned to enable the production of artificial cells with in-vivo applicability and it will pave the way towards the future development of an effective blood substitute that can remedy pervasive global blood availability and safety issues

Consortium · 5 organisations

coordinator

KATHOLIEKE UNIVERSITEIT LEUVEN

BE · €1,783,375

participant

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

FR · €414,774

participant

FONDAZIONE CASA SOLLIEVO DELLA SOFFERENZA

IT · €678,750

participant

FUNDACAO GIMM - GULBENKIAN INSTITUTE FOR MOLECULAR MEDICINE

PT · €357,598

participant

AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS

ES · €451,053

Research fields

View the official record on CORDIS →

← Find collaborators and more funded projects

Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.